These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 8324147)

  • 21. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
    Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
    J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro susceptibilities of the Bacteroides fragilis group species: change in isolation rates significantly affects overall susceptibility data.
    Aldridge KE; O'Brien M
    J Clin Microbiol; 2002 Nov; 40(11):4349-52. PubMed ID: 12409429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989.
    Cuchural GJ; Snydman DR; McDermott L; Iannini PB; Hill GB; Cleary TJ; O'Keefe JP; Pierson CL; Rihs JD; Finegold SM
    Clin Ther; 1992; 14(1):122-36. PubMed ID: 1576621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-resistance to beta-lactam-beta-lactamase inhibitor combinations and clindamycin among cefoxitin-resistant and cefoxitin-susceptible strains of the Bacteroides fragilis group.
    Aldridge KE
    Diagn Microbiol Infect Dis; 1993 Oct; 17(3):251-6. PubMed ID: 8112038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns.
    Aldridge KE; Ashcraft D; O'Brien M; Sanders CV
    Antimicrob Agents Chemother; 2003 Jan; 47(1):148-53. PubMed ID: 12499183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of newer beta-lactam agents against clinical isolates of Bacteroides fragilis and other Bacteroides species.
    O'Keefe JP; Venezio FR; DiVincenzo CA; Shatzer KL
    Antimicrob Agents Chemother; 1987 Dec; 31(12):2002-4. PubMed ID: 3439807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents.
    Aldridge KE; Henderberg A; Sanders CV
    J Antimicrob Chemother; 1990 Sep; 26(3):353-9. PubMed ID: 2228826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiology and antimicrobial resistance of B. fragilis group organisms isolated from clinical specimen and human intestinal microbiota.
    de Carvalho CB; Moreira JL; Ferreira MC
    Rev Inst Med Trop Sao Paulo; 1996; 38(5):329-35. PubMed ID: 9293074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro susceptibility of the Bacteroides fragilis group in community hospitals.
    File TM; Thomson RB; Tan JS; Salstrom SJ; Jacobs GA; Johnson L; Tan L
    Diagn Microbiol Infect Dis; 1986 Nov; 5(4):317-22. PubMed ID: 3465493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
    Betriu C; Culebras E; Gómez M; López F; Rodríguez-Avial I; Picazo JJ
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2686-90. PubMed ID: 18474575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibiotic sensitivity of the Bacteroides fragilis group in Denmark. Danish Study Group.
    Bremmelgaard A; Jansen JE; Justesen T; Gottschau A
    APMIS; 1993 Sep; 101(9):727-31. PubMed ID: 8240792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal study of susceptibilities of species of the Bacteroides fragilis group to five antimicrobial agents in three medical centers.
    Turgeon P; Turgeon V; Gourdeau M; Dubois J; Lamothe F
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2276-9. PubMed ID: 7840557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology, antimicrobial susceptibility, pathogenicity, and significance of Bacteroides fragilis group organisms isolated at Los Angeles County-University of Southern California Medical Center.
    Appleman MD; Heseltine PN; Cherubin CE
    Rev Infect Dis; 1991; 13(1):12-8. PubMed ID: 2017610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial resistance in the Bacteroides fragilis group in faecal samples from patients receiving broad-spectrum antibiotics.
    Hansen KCM; Schwensen SAF; Henriksen DP; Justesen US; Sydenham TV
    Anaerobe; 2017 Oct; 47():79-85. PubMed ID: 28445776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009.
    Snydman DR; Jacobus NV; McDermott LA; Goldstein EJ; Harrell L; Jenkins SG; Newton D; Patel R; Hecht DW
    Anaerobe; 2017 Feb; 43():21-26. PubMed ID: 27867083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
    Brook I
    J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of EUCAST disk diffusion method for susceptibility testing of the Bacteroides fragilis group isolates.
    Nagy E; Justesen US; Eitel Z; Urbán E;
    Anaerobe; 2015 Feb; 31():65-71. PubMed ID: 25464140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the bactericidal activity of clindamycin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
    Stratton CW; Weeks LS; Aldridge KE
    Diagn Microbiol Infect Dis; 1991; 14(5):377-82. PubMed ID: 1797454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
    Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Golan Y; Goldstein EJ; Finegold SM; Harrell LJ; Hecht DW; Jenkins SG; Pierson C; Venezia R; Yu V; Rihs J; Gorbach SL
    Antimicrob Agents Chemother; 2007 May; 51(5):1649-55. PubMed ID: 17283189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982.
    Cuchural GJ; Tally FP; Jacobus NV; Gorbach SL; Aldridge K; Cleary T; Finegold SM; Hill G; Iannini P; O'Keefe JP
    Antimicrob Agents Chemother; 1984 Aug; 26(2):145-8. PubMed ID: 6486758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.